<DOC>
	<DOCNO>NCT01077739</DOCNO>
	<brief_summary>This open-label single arm study evaluate efficacy safety Avastin add XELOX FOLFOX patient metastatic colorectal cancer disease progression 1st line therapy FOLFIRI plus Avastin . Patients receive either Avastin ( 7.5mg/kg iv infusion every 3 week ) standard XELOX ( Xeloda [ capecitabine ] plus oxaliplatin ) chemotherapy Avastin ( 5 mg/kg iv infusion every 2 week ) standard FOLFOX ( 5-FU leucovorin plus oxaliplatin ) chemotherapy . The anticipated time study treatment disease progression , target sample size 100 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) With XELOX FOLFOX Patients With Metastatic Colorectal Cancer Disease Progression Under First-line FOLFIRI Avastin</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>adult patient &gt; /=18 year age metastatic colorectal cancer least 1 measurable lesion accord RECIST v. 1.1 patient disease progression prior FOLFIRI + Avastin therapy candidate primary metastasectomy disease progression &lt; /= 8 week last dose Avastin ECOG &lt; /=2 No 8 week 1stline treatment FOLFIRI + Avastin 2ndline treatment XELOX FOLFOX + Avastin disease progression &gt; 8 week last Avastin administration clinically significant cardiovascular disease CNS disease except treated brain metastasis history malignancy within 2 year prior start study treatment ( exception curatively treat basal squamous cell carcinoma skin situ carcinoma cervix ) major surgery , open biopsy , significant traumatic injury within 28 day prior start study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>